The core patent technologies that underpin the Enhanced Electrochemiluminescence (EECL) platform technology of Accucise Diagnostics are multifarious.

As a well-established immunoassay platform technology, ECL has historically been designed with ruthenium tris-bipyridine ([Ru(bpy)3]2+) as its electrochemiluminescent unit since its inception. Despite the continuous design, synthesis, and evaluation of new ECL luminophores over the past two decades, the actual ECL label utilized in clinical immunoassays has consistently been limited to [Ru(bpy)3]2+ with bio-coupling units, such as [4-(N-succinimidyloxycarbonylpropyl)-4’-methyl-2,2’-bipyridine] bis-(2,2’-bipyridine)ruthenium (II) dihexafluorophosphate. Many ECL luminophores, despite the claim of potential application value by academic researchers, have not been rigorously evaluated in ECL immunoassays and, therefore, have not been adopted in clinical medical diagnostics. For Neutral Ruthenium Complexes (NRC) claimed in patent application PCT/IB2014/001115, Accucise Diagnostics has fully evaluated the luminescence properties and application details in immunoassays, and thus elected to invest in the development of an NRC-based EECL platform. Also, it has entered into an exclusive implementation license agreement with the patent holder prior to the patent being granted in China and the United States. Currently, NRC is patented in China and the United States as a broad category of ECL light-emitting labels, with its application in immunoassay being exclusively developed by Accucise Diagnostics.

In relation to the optimization of the electrochemiluminescence signal generation process, Accucise Diagnostics has filed a patent application (Chinese Patent Application No. 202110957653.9) of achieving a high signal-to-noise ratio through voltage adjustment.

Furthermore, to eliminate the interference of biotin in samples on test outcomes, Accucise Diagnostics has developed the world’s first biotin-free electrochemiluminescence immunoassay reagent system (see the Figure on the right), and filed a patent application (Chinese Patent Application No. 202111047504.5) for kits not involving biotin/streptavidin coupling reactions.